BNT3214

PreclinicalSmall molecule

BioNTech

BNT3214 is one of 2 small molecule programs targeting Advanced Solid Tumor Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Solid Tumor CancerRecruiting

Advanced Solid Tumor CancerPreclinical

Recruiting

Competition

Competitive Landscape

1 competitor in Advanced Solid Tumor Cancer

#DrugCompanyPhaseTrials

Beyfortus

BeiGene

Preclinical

1 2

BNT3214

BioNTech

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

PreclinicalRecruiting

Advanced Solid Tumor Cancer

NCT07455734

Clinical

Trials by Indication[1]

Advanced Solid Tumor Cancer1 trial

A Phase I/IIa, First-in-human, Open-label, Multi-site, Multi-regional, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumors

Recruiting· BioNTech logo

BioNTech·Preclinical·NCT07455734·533 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BNT3214. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BNT3214 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BNT3214. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BioNTech company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: BioNTech

BNT3214

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Advanced Solid Tumor Cancer1 trial

References

Drug Info

Quick Facts

Related News